---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000003"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:17:24.351996+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme raises 2025 guidance: rev $1.15-1.225B, adj EBITDA $755-805M, $250M ASR

## Summary
- Raises 2025 total revenue guidance to $1,150-$1,225M, representing 16-23% YoY growth from 2024 midpoint.
- Raises 2025 adjusted EBITDA guidance to $755-$805M (24-32% YoY) and non-GAAP diluted EPS to $4.95-$5.35 (21-30% YoY).
- Announces new $250M accelerated share repurchase (ASR) under existing $750M share repurchase program.
- Reiterates 2024 preliminary unaudited guidance: revenue $970-$1,020M, adjusted EBITDA $595-$625M, non-GAAP EPS $4.00-$4.20.

## SEC filing metadata
- accession: 0001159036-25-000003
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000003/0001159036-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000003/halo-20250108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000003
- JSON: https://secwatch.observer/filing/0001159036-25-000003.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.